UTXO Acquisition Inc.

UTXO Acquisition Inc.

Oct 16, 2020 by Roman Developer

MANAGEMENT & BOARD


Executive Officers

Wei Huang, Ph.D., 41
Chief Executive Officer

Dr. Wei Huang, during a multiple-year career as a technique leader and entrepreneur, has served in many leading management and technical leadership roles in high-tech industries that require extensive technological knowledge and critical thinking, including blockchain technology, AI, big data and e-commerce industries. These experiences, along with his participation in the development of multiple businesses, including big data and AI projects in Shenzhen, have led to long term business relationships with VC funds, individual investors and state-owned companies. He is a founder of and currently serving as the Chairman of the Board of Dake Data, Ltd. in Shenzhen. Dr. Huang founded Dake Data, LTD in 2017, working with a team of talented professionals using Dake’s proprietary AI, Blockchain and Cloud computing (ABC solution) solution to serve different industries, including supply chain finance, education and the fashion business. Dr. Huang’s unique experience in both management and technology field have helped increase company performance and promote sustainable growth through internal innovation. In 2019, Dake Data was selected as “China’s Outstanding Innovative Blockchain Company” by the China blockchain Innovation Forum. Before Dr. Huang founded Dake Data, he served as technique leader in the oil and gas industry. From 2013 to 2018, Dr. Huang worked in ION geophysical as a technical advisor for various projects. Dr. Huang has earned his reputation by applying datasets, technology, and industry expertise to discover the underlying current and future value of oil and gas opportunities. From 2011 to 2013, Dr. Huang served as a project manager with Schlumberger North America, the large oil and gas services company, providing geophysical advice on all aspects of full waveform inversion technology and assisting with the marketing and sales effort with technical presentations to clients. His responsibilities include supporting innovation through defining the research and development focus of the group; communicating with domestic and foreign enterprises to evaluate cooperative projects and to explore methods to expand the cooperation. Dr. Huang Holds a bachelor’s degree from University of Science and Technology of China, a master’s degree in mathematics from the University of Wisconsin and a PhD degree in Geophysics from the University of Houston. Dr. Huang has published more than a dozen papers and holds two international patents.


Yuanyuan Huang, Ph.D., 41
Chief Financial Officer & Chief Operating Officer

Dr. Yuanyuan Huang, has over 10 years of experience as a financial professional providing investment banking services to start-ups, small to middle-sized companies, and venture capital and private equity firms. Since June 2018, Dr. Yuanyuan Huang has served as the Managing Member of Fundin, LLC, a consulting firm providing information technology consulting services to private real estate equity funds and developers. Since September, 2018, Dr. Yuanyuan Huang also served as Venture Partner of Hongkun USA, a real estate developer and investment company in New York, and led a team toto develop its fund administration and investor relationship information system. Between 2008 and 2018, Dr. Yuanyuan Huang worked at several boutique brokerage firms. During his career as an investment banker, he worked with other financial professionals in private placements, reverse mergers, and corporation finance. Before Dr. Yuanyuan Huang began his financial career, he obtained his Ph.D. in Physics from William and Mary in Williamsburg, Virginia in 2007, and a master’s degree in Finance from the George Washington University in Washington, D.C. in 2008. He is also the main contributor to a proprietary algorithm for analyzing Solid State Nuclear Magnetic Spectrum.


Mengyi (Jason) Ye, 32
Chief Legal Officer, Director, and Chairman of the Board, Class C

Mr. Mengyi (Jason) Ye, is a Partner of Ortoli Rosenstadt LLP. Mr. Ye concentrates his practice on cross-border corporate and capital market transactions and has represented many domestic and international companies in the healthcare sector, investment banks and institutional investors on transactions including initial and secondary public offerings, alternative public offerings, and private placements. Mr. Ye also regularly represents public companies regarding their NYSE or Nasdaq initial listing and post-listing compliance. Mr. Ye also advises public companies on general corporate governance and federal filing requirements under the Securities Act of 1933 and Securities Exchange Act of 1934. Mr. Ye was selected to the 2020 New York Metro Corporate and Securities Law “Super Lawyer” Rising Stars list. Mr. Ye holds a Juris Doctorate degree from Rutgers University and a bachelor’s degree from New York University.


Board of Directors

Jinxiu (Lisa) Liu, 42
Independent Director, Class B

Ms. Jinxiu Liu specializes in financial management, bond financing, e-commerce, internet-based business capital management, and business operations. Currently, Ms. Liu is the Managing Partner at CDF Capital, and a director of Shenzhen Innovation Development Hub Innovation Center Co., Ltd. with over ten (10) years financial and accounting experience in public companies, and was a senior accounting manager at China Telecom Group, Wal-Mart China, and Tencent. She is a Fellow of Chartered Certified Accountant (FCCA) of Association of Chartered Certified Accountants (ACCA), and a chartered member of Chinese Institute of Certified Public Accountants (CICPA). In addition to Ms. Liu’s financial industry experience, she also lectures at multiple education and professional institutes, including the Department of Accounting of Economics and Management School at Wuhan University, Beijing National Accounting Institute, Xiamen National Accounting Institute, Chinese Institute of Certified Public Accountants, Shenzhen Institute of Certified Public Accountants, and Guangzhou Institute of Certified Public Accounts.


Jiaming Li, 33
Independent Director, Class B

Dr. Jiaming Li is the Partner of TCC Capital since Aug 2019. Before Dr. Li joined TCC, he previously served as CEO of the Asset Management Center of Sinatay Insurance Co., Ltd, a life insurance company registered in China, and managed USD 11.6 billion assets, focus on fixed income, equity/debt investment and real estate. Dr. Li served as President of Silverbirch Hotel& Resorts Asset Management where he managed real estate funds with USD 1.2 billion in assets under management before joining Sinatay Insurance. He has a Ph. D in Finance from Fordham University in the United States, and postdoctoral fellow from Peking University.


Marta New, 41
Independent Director, Class A

Ms. New has served as the president and chief executive officer of Radyus Research Inc. since October 2019. From September 2016 to July 2019, Dr. New served as a partner of Agent Capital, LLC, during which time Dr. New participated in multiple deals in oncology, immunology and rare disease areas including Orchard Therapeutics (Nasdaq: ORTX) and Precision Biosciences (Nasdaq: DITL). Prior to that, Dr. New served as a principal investor at Baxter Ventures, a corporate venture arm of Baxter International (NYSE: BAX) from December 2013 to August 2016. Dr. New received her bachelor’s degree in biology from University of Novi Sad in Republic of Serbia in 2002. Dr. New received her Ph.D. in microbiology and immunology from University of Illinois in 2006. Dr. New received an MBA degree from Northwestern University in 2011.


John Reardon, 63
Independent Director, Class A

Mr. Reardon is an accomplished healthcare executive, entrepreneur and investor working at the forefront of digital health and telemedicine. For the past 20 years Mr. Reardon has helped three Private Equity/Venture Capital funds focused primarily on Digital Health/Tele-Medicine and Technology-Enabled Healthcare Services. His portfolio includes: TelaDoc (NYSE: TDOC), Advanced ICU Care, Progeny Health, ArroHealth (acquired by CIOX Health), Acclaris (acquired by Willis, Towers, Watson NASDAQ: WLTW), HealthMedX (acquired by Netsmart Technologies NASDAQ: NTST) and Aethon (acquired by OTCMKTS: SGGKF). Today, Mr. Reardon works directly with growth stage digital health companies providing strategy and fund-raising assistance. Mr. Reardon holds an MBA from the Anderson School at the University of California, Los Angeles and holds BS Degrees in History and Economics from Arizona State University.